Please login to the form below
3
Revenue 2017Roche
The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Roche's 2013 sales performance.
FDA delays review of Novartis’ MS drug ofatumumab
If approved, ofatumumab (OMB157) will be a direct rival to Roche’s fast-growing MS therapy Ocrevus (ocrelizumab), which has exploded since its launch in 2017 and had revenues of
ASCO: Merck’s Keytruda tops chemo in MSI-H colorectal cancer
Investigators could choose the chemotherapy-based regimen they used as the comparator in the trial, and a number opted for the combination of Roche’s Avastin (bevacizumab) with mFOLFOX6, which is
ASCO: Bavencio boosts survival post-chemo in bladder cancer
AstraZeneca’s Imfinzi (durvalumab) and Roche’s Tecentriq (atezolizumab) which have transformed the prospects for bladder cancer patients.
Roche/Gilead tag team fights COVID-19 with Actemra/remdesivir
Roche and Gilead Sciences are joining forcers to fight COVID-19 with a 450-patient trial that will combine two drugs already being tested against coronavirus as monotherapies. ... The study – called REMDACTA – will start enrolling hospitalised
Finalists 2020
by Weber Shandwick. for Roche. Peter Impey. 90TEN. Rebecca Tait. 90TEN. .
Data provided by GlobalData
GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.
To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology
COVID-19 Updates and Daily News
Featured jobs
- Biogen delays filing of Alzheimer’s drug, which hits its share price
- Regeneron says antibody for COVID-19 could be ready this year
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Amgen adds Otezla to the COVID-19 candidate list
- Alnylam and Vir plan gene-silencing attack on COVID-19 virus
- Roche/Gilead tag team fights COVID-19 with Actemra/remdesivir
- Moderna to begin pivotal phase 3 trial of COVID-19 vaccine in July
- Impetus Digital Fireside Chat with Susanne Somerville of Chronicled
- Impetus Digital Fireside Chat with Bechara Saab of Mobio Interactive
- FDA delays review of Novartis’ MS drug ofatumumab
- Sanofi makes ‘best-in-class’ claim for Sarclisa in myeloma
- Q&A: Kay Wesley
PMHub
Dovetail
About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
